| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JTOS.2015.12.007 |
| P8608 | Fatcat ID | release_a74zijjrtjhzjgtt2jrcent25y |
| P932 | PMC publication ID | 4842325 |
| P698 | PubMed publication ID | 26807724 |
| P50 | author | Elizabeth R Felix | Q60328728 |
| Allison L McClellan | Q87153185 | ||
| P2093 | author name string | Roy C Levitt | |
| Anat Galor | |||
| Konstantinos D Sarantopoulos | |||
| Nicole L Lanza | |||
| Hatim Batawi | |||
| P2860 | cites work | Matrix metalloproteinase 9 and transglutaminase 2 expression at the ocular surface in patients with different forms of dry eye disease. | Q51112094 |
| Reversibility of dry eye deceleration after topical cyclosporine 0.05% withdrawal. | Q53143850 | ||
| Utility assessment among patients with dry eye disease. | Q53379868 | ||
| Measurement of corneal sensitivity to mechanical and chemical stimulation with a CO2 esthesiometer | Q59282389 | ||
| Desiccating Stress Induces T Cell-Mediated Sjogren's Syndrome-Like Lacrimal Keratoconjunctivitis | Q61851332 | ||
| Anti-inflammatory therapy of dry eye | Q79317939 | ||
| The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007) | Q80347907 | ||
| The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007) | Q80347909 | ||
| Eccentric variation of corneal sensitivity to pneumatic stimulation at different temperatures and with CO2 | Q80699831 | ||
| Impact of ocular surface symptoms on quality of life in a United States Veterans Affairs population | Q24169749 | ||
| Depression, post-traumatic stress disorder, and dry eye syndrome: a study utilizing the national United States Veterans Affairs administrative database | Q24169750 | ||
| Dry eye: an inflammatory ocular disease | Q26852044 | ||
| Prevalence of dry eye syndrome among US women | Q28196875 | ||
| Tear film MMP accumulation and corneal disease | Q28346325 | ||
| Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. | Q30813799 | ||
| Apical corneal barrier disruption in experimental murine dry eye is abrogated by methylprednisolone and doxycycline | Q30818365 | ||
| The corneal pain system. Part I: the missing piece of the dry eye puzzle | Q33353030 | ||
| Prevalence of dry eye disease among US men: estimates from the Physicians' Health Studies | Q33720070 | ||
| MMP-9 and the perioperative management of LASIK surgery | Q33887903 | ||
| Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction: a comparative clinical and spectroscopic pilot study | Q34066784 | ||
| Effect of inflammation on lacrimal gland function. | Q34338027 | ||
| Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. | Q34544207 | ||
| Dry eye as a mucosal autoimmune disease | Q34647761 | ||
| Prevalence, risk factors, and morbidity of eye lid laxity in a veteran population | Q34813208 | ||
| Physiology and pathophysiology of matrix metalloproteases. | Q35007715 | ||
| Matrix metalloproteinase-9 knockout confers resistance to corneal epithelial barrier disruption in experimental dry eye | Q35083557 | ||
| Neuropathic ocular pain: an important yet underevaluated feature of dry eye. | Q35196826 | ||
| Prospective, multicenter, clinical evaluation of point-of-care matrix metalloproteinase-9 test for confirming dry eye disease | Q35197785 | ||
| Frequent association of delayed tear clearance in ocular irritation | Q35305507 | ||
| IL-1β promotes corneal epithelial cell migration by increasing MMP-9 expression through NF-κB- and AP-1-dependent pathways | Q36665694 | ||
| Production and activity of matrix metalloproteinase-9 on the ocular surface increase in dysfunctional tear syndrome | Q36676823 | ||
| Dry eye disease: an immune-mediated ocular surface disorder | Q36916372 | ||
| Advancements in anti-inflammatory therapy for dry eye syndrome | Q37607886 | ||
| Impact of dry eye disease and treatment on quality of life | Q37751734 | ||
| The Matrix Metalloproteinase 9 Point-of-Care Test in Dry Eye | Q38724515 | ||
| Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group | Q41730611 | ||
| EMMPRIN modulates epithelial barrier function through a MMP-mediated occludin cleavage: implications in dry eye disease | Q41980966 | ||
| Pro- and anti-inflammatory forms of interleukin-1 in the tear fluid and conjunctiva of patients with dry-eye disease | Q43723395 | ||
| Gelatinase B/MMP-9 as an inflammatory marker enzyme in mouse zymosan peritonitis: comparison of phase-specific and cell-specific production by mast cells, macrophages and neutrophils | Q43894430 | ||
| Dry eye symptom severity and persistence are associated with symptoms of neuropathic pain. | Q44054312 | ||
| Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): Discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses | Q44896506 | ||
| A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance | Q45056544 | ||
| Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface | Q45158772 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 216-223 | |
| P577 | publication date | 2016-01-22 | |
| P1433 | published in | The Ocular Surface | Q15764153 |
| P1476 | title | Dry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients | |
| P478 | volume | 14 |
| Q46718255 | Corneal Nerve Regeneration after Self-Retained Cryopreserved Amniotic Membrane in Dry Eye Disease |
| Q64090804 | Corneal biomechanical alterations in patients with chronic ocular Graft Versus-Host Disease |
| Q90079719 | Dry Eye Disease: Emerging Approaches to Disease Analysis and Therapy |
| Q47639135 | Dry eye syndrome: developments and lifitegrast in perspective |
| Q96022836 | Evaluation of ocular surface disease in elderly patients with glaucoma: expression of matrix metalloproteinase-9 in tears |
| Q64080811 | Extracellular MMP-9-Based Assessment of Ocular Surface Inflammation in Patients with Primary Open-Angle Glaucoma |
| Q99551257 | In vitro validation of the tear matrix metalloproteinase 9 in-situ immunoassay |
| Q50599398 | Intense pulsed light treatment and meibomian gland expression for moderate to advanced meibomian gland dysfunction. |
| Q58599953 | Matrix Metalloproteinase 9 Point-of-Care Immunoassay Result Predicts Response to Topical Cyclosporine Treatment in Dry Eye Disease |
| Q47739620 | Neuropathic pain and dry eye. |
| Q39030112 | Presence or absence of ocular surface inflammation directs clinical and therapeutic management of dry eye. |
| Q46355642 | Randomised controlled trial of topical antibacterial Manuka (Leptospermum species) honey for evaporative dry eye due to meibomian gland dysfunction |
| Q90403125 | Role of tear film biomarkers in the diagnosis and management of dry eye disease |
| Q38652990 | TFOS DEWS II Tear Film Report. |
| Q55174805 | Tear Volume-based Diagnostic Classification for Tear Dysfunction. |
| Q33756582 | The Growing Need for Validated Biomarkers and Endpoints for Dry Eye Clinical Research |
| Q38724515 | The Matrix Metalloproteinase 9 Point-of-Care Test in Dry Eye |
| Q47884949 | The Pathophysiology of Dry Eye Disease: What We Know and Future Directions for Research |
| Q47424328 | Update in Current Diagnostics and Therapeutics of Dry Eye Disease. |
Search more.